Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of PF-05221304 in Hepatic Impairment
NCT03309202Phase 1Completed
- Sponsor
- Pfizer
- Start
- Dec 2017
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of clesacostat in Nonalcoholic steatohepatitis (NASH) (4 cohorts), sponsored by Pfizer. Primary endpoints: Maximum Plasma Concentration, Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time and 3 more. Started Dec 2017; status: completed.
02
Drugs
clesacostat
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03309202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03309202.